A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease
Sofia Tzimopoulou(GlaxoSmithKline (United Kingdom)), Paul M. Matthews(Rosalind Franklin Institute), Julian C. Matthews(Manchester Academic Health Science Centre), Graham E. Searle(Unknown), Brandon Whitcher(Royal Marsden NHS Foundation Trust), Narinder Lotay(GlaxoSmithKline (United Kingdom)), William Hallett(GlaxoSmithKline (United Kingdom)), Andy Brown(University of Cambridge), Dan Bandy(Alzheimer's Association), Eric M. Reiman(Alzheimer's Association), Marina Zvartau‐Hind(GlaxoSmithKline (United Kingdom)), Ian Dixon(GlaxoSmithKline (United Kingdom)), Nick Bird(GlaxoSmithKline (United Kingdom)), Thomas E. Nichols(University of Oxford), Michael Gold(National Centre for Immunisation Research & Surveillance), Mary Castiglia(Research Triangle Park Foundation), Barbara Jeter(Research Triangle Park Foundation), Kewei Chen(Good Samaritan Medical Center), Vincent J. Cunningham(GlaxoSmithKline (United Kingdom)), Eugenii A. Rabiner(GlaxoSmithKline (United Kingdom)), Robert Lai(Eisai (United Kingdom)), Prafull Mistry(GlaxoSmithKline (United Kingdom))
Cited by 109
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data
|NeuroImage|2006|6.6k
A Resilient, Low-Frequency, Small-World Human Brain Functional Network with Highly Connected Association Cortical Hubs
|Journal of Neuroscience|2006|2.5k
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging
|Nature Neuroscience|2003|2.4k
Large recurrent microdeletions associated with schizophrenia
|Nature|2008|1.8k